Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan (CUARTET)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04601441 |
Recruitment Status :
Recruiting
First Posted : October 23, 2020
Last Update Posted : December 8, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Castration-sensitive Prostate Cancer | Drug: Apalutamide | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Screening |
Official Title: | Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan |
Actual Study Start Date : | November 6, 2020 |
Estimated Primary Completion Date : | March 31, 2025 |
Estimated Study Completion Date : | March 31, 2025 |
Arm | Intervention/treatment |
---|---|
Apalutamide
Apalutamide 240 mg administered orally once a day as four 60 mg tablets
|
Drug: Apalutamide
Apalutamide 240 mg administered orally once a day as four 60 mg tablets |
- Changes in genomic alterations of 73 PC driver genes between pre- and posttreatment of apalutamide. [ Time Frame: Three years or more, 4.5 years or less ]Seventy-three PC driver genes from ctDNA including ARID1A, HSD3B1, MDM4, AKT3, MSH2, MSH6, ERCC3, NFE2L2, IDH1, FANCD2, MLH1, CTNNB1, FOXP1, RYBP, PIK3CB, ATR, PIK3CA, FBXW7, PIK3R1, CHD1, APC, FANCE, CDK6, MET, BRAF, CUL1, KMT2C, NKX3-1, CLU, NCOA2, MYC, CDKN2A, FANCG, FANCC, PTEN, FANCF, CCND1, ATM, ZBTB16, CDKN1B, KRAS, KMT2D, CDK4, MDM2, BRCA2, RB1, ERCC5, FOXA1, RAD51B, AKT1, IDH2, ERCC4, ZFHX3, FANCA, TP53, CDK12, BRCA1, SPOP, RNF43, RAD51C, AKT2, ERCC2, ERCC1, ASXL1, GNAS, RUNX1, ERG, TMPRSS2, KDM6A, AR, MED12, SMARCA1, and PALB2.
- The proportion of participants who achieve nadir PSA ≤0.2 ng/mL stratified by baseline genomic alterations for 73 PC driver genes [ Time Frame: Three years or more, 4.5 years or less ]The proportion of participants who achieve nadir PSA ≤0.2 ng/mL is defined as the proportion of participants who achieve nadir PSA less than 0.2 ng/mL from apalutamide initiation.
- PSA-PFS stratified by baseline genomic alterations for 73 PC driver genes [ Time Frame: Three years or more, 4.5 years or less ]The PSA-PFS is defined as the duration from apalutamide initiation to either PSA progression or death, whichever occurs first. The PSA progression will be determined according to the PCWG3 criteria.
- PFS stratified by baseline genomic alterations for 73 PC driver genes [ Time Frame: Three years or more, 4.5 years or less ]The PFS is defined as the duration from apalutamide initiation to either radiographic progression, clinical progression or death, whichever occurs first. The radiographic and clinical progression will be determined by an investigator's discretion.
- OS stratified by baseline genomic alterations for 73 PC driver genes [ Time Frame: Three years or more, 4.5 years or less ]The OS is defined as the duration from apalutamide initiation to any death.
- Time to CRPC stratified by baseline genomic alterations for 73 PC driver genes [ Time Frame: Three years or more, 4.5 years or less ]The time to CRPC is defined as the duration from apalutamide initiation to developing CRPC. The CRPC will be determined according to European Association of Urology (EAU) guidelines 2019.
- PFS2 stratified by baseline genomic alterations for 73 PC driver genes [ Time Frame: Three years or more, 4.5 years or less ]The PFS2 is defined as the duration from apalutamide initiation to disease progression (PSA progression, radiographic progression, or clinical progression) on the first subsequent therapy for prostate cancer, whichever occurred first. The PSA progression will be determined according to the PCWG3 criteria. The radiographic and clinical progression will be determined by an investigator's discretion.
- Safety in the usual clinical practice based on adverse events [ Time Frame: From apalutamide initiation to 30 days after the last dose ]Safety observational period is defined as the treatment phase in this study. Adverse events that occur within 30 days after the last dose of apalutamide will be collected, except for lost to follow-up, death, or withdrawal of consent for study participation. For each adverse event, the percentage of participants who experience at least 1 occurrence of the given event will be summarized.
- Safety in the usual clinical practice based on potential skin rash events [ Time Frame: From apalutamide initiation to 30 days after the last dose ]Safety observational period is defined as the treatment phase in this study. Potential skin rash events that occur within 30 days after the last dose of apalutamide will be collected, except for lost to follow-up, death, or withdrawal of consent for study participation. The percentage of participants who experience at least 1 occurrence of the given event will be summarized.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men aged ≥20 years.
- Participant has documented diagnosis of metastatic PC with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology.
- Participant has metastatic PC that is castration naïve or castration sensitive and is permitted to receive less than 6-months ADT or CAB before registration and less than 36-months neoadjuvant or adjuvant hormonal therapy.
- If a participant is treated with ADT or CAB, he has maintained a response to hormonal therapy of stable disease or better, by investigator assessment of imaging and PSA.
- Participant is willing to receive apalutamide for mCSPC in the participating site of this study.
- Participant is of Japanese nationality.
- Participant must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
Exclusion Criteria:
- Participant does not agree to assess ctDNA including 73 PC driver genes, SNPs, and HLA typing.
- Participant has received any prior therapy of abiraterone, docetaxel, enzalutamide, apalutamide or darolutamide.
- Participant has known allergies, hypersensitivity, or intolerance to apalutamide or its excipients (refer to the package insert).
- Participant has contraindications to the use of ADT based on routine treatment.
- Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the evaluation of active double cancer, etc.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04601441
Contact: Hiroshi Yoshida | +81-3-3830-1074 | ctDNA@a2healthcare.com |
Japan | |
Kindai University Hospital | Recruiting |
Ōsaka-sayama, Osaka, Japan, 589-851 | |
Contact: Hirotsugu Uemura, MD, PhD | |
Principal Investigator: Hirotsugu Uemura, MD, PhD |
Study Chair: | Hirotsugu Uemura, MD, PhD | Department of Urology, Kindai University Faculty of Medicine |
Responsible Party: | Hirotsugu Uemura, Professor, Kindai University |
ClinicalTrials.gov Identifier: | NCT04601441 |
Other Study ID Numbers: |
56021927PCR4013 jRCTs071200040 ( Registry Identifier: Japan Registry of Clinical Trial (jRCT) ) 56021927PCR4013 ( Other Grant/Funding Number: Janssen Pharmaceutical K.K. ) |
First Posted: | October 23, 2020 Key Record Dates |
Last Update Posted: | December 8, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Prostatic Neoplasms Hypersensitivity Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms |
Genital Diseases, Male Genital Diseases Urogenital Diseases Prostatic Diseases Male Urogenital Diseases Immune System Diseases |